Bal Pharma Limited
NSE: BALPHARMA BSE: BALPHARMA
NSE
93.70
-2.48 (-2.58%)
Prev Close
96.18
Open Price
91.5
Volume
11,869
Today Low / High
91.5 / 95.6
52 WK Low / High
78.06 / 157.98
Range
89 - 98
BSE
94.80
-1.40 (-1.46%)
Prev Close
96.2
Open Price
96.2
Volume
747
Today Low / High
93.5 / 96.2
52 WK Low / High
76.3 / 157.9
Range
90 - 100
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 93.7 (target range: 89 - 98), reflecting a change of -2.48 (-2.5785%). On the BSE, it is listed at 94.8 (target range: 90 - 100), showing a change of -1.4 (-1.4553%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
09 May
91.50
2.55%
08 May
96.05
0.14%
07 May
94.01
2.02%
06 May
100.10
-3.68%
05 May
100.95
-0.63%
02 May
102.01
-1.04%
30 Apr
104.01
-1.79%
29 Apr
103.99
-0.57%
28 Apr
107.01
-3.20%
25 Apr
109.02
-1.72%
24 Apr
111.01
-1.91%
23 Apr
109.01
2.16%
22 Apr
106.01
3.33%
21 Apr
107.00
-0.93%
17 Apr
107.88
-2.75%
16 Apr
106.00
0.39%
15 Apr
105.70
0.23%
Bal Pharma Limited Graph
Bal Pharma Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Bal Pharma Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 93.70, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 94.80 | 95.75 | 86.17 - 105.32 |
| 96.70 | 77.36 - 116.04 | ||
| 97.64 | 68.35 - 126.94 | ||
| Bearish Scenario | 94.80 | 93.85 | 84.47 - 103.24 |
| 92.90 | 74.32 - 111.48 | ||
| 91.96 | 64.37 - 119.54 |
Overview of Bal Pharma Limited
ISIN
INE083D01012
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
86,326
Market Cap
1,491,788,330
Last Dividend
1.2
Official Website
IPO Date
2006-05-08
DCF Diff
-234.15
DCF
352
Financial Ratios Every Investor Needs
Stock Dividend of BALPHARMA
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2024-09-17 | September 17, 24 | 1.2 | 1.2 | 2024-09-18 | 2024-10-25 | |
| 2023-09-18 | September 18, 23 | 1 | 1 | 2023-09-18 | 2023-10-25 | |
| 2022-09-13 | September 13, 22 | 1 | 1 | 2022-09-14 | 2022-10-19 | |
| 2021-09-16 | September 16, 21 | 1 | 1 | 2021-09-17 | 2021-10-24 | |
| 2019-09-17 | September 17, 19 | 1 | 1 | 2019-09-18 | 2019-10-23 | 2019-05-31 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 339.22 Cr | 262.20 Cr | 77.02 Cr | 0.2270 | 0.00 Cr | 4.27 Cr | 21.46 Cr | 7.39 Cr | 4.94 | 32.02 Cr | 0.0218 |
| 2023-03-31 | 304.22 Cr | 172.77 Cr | 131.45 Cr | 0.4321 | 4.92 Cr | 3.42 Cr | 16.94 Cr | 2.57 Cr | 1.64 | 24.50 Cr | 0.0085 |
| 2022-03-31 | 281.21 Cr | 169.73 Cr | 111.48 Cr | 0.3964 | 3.20 Cr | 2.71 Cr | 14.44 Cr | 5.61 Cr | 3.79 | 28.76 Cr | 0.0200 |
| 2021-03-31 | 250.53 Cr | 151.23 Cr | 99.30 Cr | 0.3964 | 2.02 Cr | 2.13 Cr | 17.09 Cr | 4.74 Cr | 3.34 | 25.78 Cr | 0.0189 |
| 2020-03-31 | 171.09 Cr | 85.60 Cr | 85.49 Cr | 0.4997 | 2.83 Cr | 2.54 Cr | -2.61 Cr | -12.22 Cr | -8.62 | 4.89 Cr | -0.0714 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 4.20 Cr | 319.53 Cr | 250.26 Cr | 69.2943 Cr | 142.25 Cr | 138.05 Cr | 87.81 Cr | 64.25 Cr | 0.00 Cr | 0.00 Cr | 0.40 Cr | 203.0424 Cr |
| 2023-03-31 | 1.49 Cr | 313.17 Cr | 249.47 Cr | 63.7891 Cr | 131.00 Cr | 129.51 Cr | 98.01 Cr | 62.18 Cr | 12.23 Cr | 0.45 Cr | -4.09 Cr | 209.3344 Cr |
| 2022-03-31 | 1.11 Cr | 260.53 Cr | 202.04 Cr | 58.6268 Cr | 106.66 Cr | 105.54 Cr | 74.40 Cr | 57.28 Cr | 19.20 Cr | 1.83 Cr | -4.39 Cr | 165.6448 Cr |
| 2021-03-31 | 1.02 Cr | 240.08 Cr | 186.73 Cr | 53.5814 Cr | 111.95 Cr | 110.92 Cr | 60.39 Cr | 57.51 Cr | 11.23 Cr | 1.95 Cr | -2.14 Cr | 152.5329 Cr |
| 2020-03-31 | 0.86 Cr | 238.39 Cr | 193.05 Cr | 52.4261 Cr | 120.42 Cr | 119.56 Cr | 67.71 Cr | 63.77 Cr | 19.38 Cr | 2.09 Cr | 1.02 Cr | 159.4915 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 22.8058 Cr | -18.8909 Cr | -1.2063 Cr | 11.8258 Cr | 2.7087 Cr | 4.1958 Cr | -10.9800 Cr | 7.3923 Cr | 16.1876 Cr | -1.5690 Cr | 10.1936 Cr |
| 2023-03-31 | -1.8435 Cr | -22.1824 Cr | 24.4002 Cr | -16.4889 Cr | 0.3744 Cr | 1.4871 Cr | -14.6454 Cr | 4.7485 Cr | 11.7021 Cr | -1.5572 Cr | -23.6094 Cr |
| 2022-03-31 | 27.7084 Cr | -9.4848 Cr | -18.1343 Cr | 19.2391 Cr | 0.0893 Cr | 1.1128 Cr | -8.4693 Cr | 9.1825 Cr | -6.2486 Cr | -1.4822 Cr | -14.0103 Cr |
| 2021-03-31 | 21.7812 Cr | -4.9805 Cr | -16.6324 Cr | 18.3678 Cr | 0.1647 Cr | 1.0234 Cr | -3.4134 Cr | 4.1027 Cr | -12.9225 Cr | -0.2913 Cr | 7.3261 Cr |
| 2020-03-31 | 23.1012 Cr | -4.7053 Cr | -19.9732 Cr | 18.0379 Cr | -1.5773 Cr | 0.8587 Cr | -5.0633 Cr | -13.5293 Cr | -6.2488 Cr | -1.4172 Cr | 2.0398 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 73.15 Cr | 36.85 Cr | 36.30 Cr | 0.4962 | 5.07 Cr | 0.48 Cr | 0.33 | 8.26 Cr | 0.0066 |
| 2024-09-30 | 73.69 Cr | 37.99 Cr | 35.70 Cr | 0.4845 | 5.22 Cr | 1.04 Cr | 0.65 | 7.49 Cr | 0.0141 |
| 2024-06-30 | 74.36 Cr | 56.41 Cr | 17.95 Cr | 0.2413 | 4.04 Cr | 0.26 Cr | 0.16 | 7.28 Cr | 0.0035 |
| 2024-03-31 | 94.63 Cr | 71.56 Cr | 23.07 Cr | 0.2438 | 7.44 Cr | 5.47 Cr | 3.73 | 12.05 Cr | 0.0578 |
| 2023-12-31 | 81.66 Cr | 45.85 Cr | 35.82 Cr | 0.4386 | 4.93 Cr | 0.89 Cr | 0.56 | 7.89 Cr | 0.0109 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 1.95 Cr | 24.21 Cr | 26.16 Cr | 0.00 Cr | 89.87 Cr | 248.21 Cr | 65.65 Cr | 339.51 Cr | 270.75 Cr |
| 2024-03-31 | 4.20 Cr | 15.73 Cr | 20.05 Cr | 99.62 Cr | 87.81 Cr | 235.01 Cr | 64.25 Cr | 319.53 Cr | 251.13 Cr |
| 2023-12-31 | -8.38 Cr | 16.76 Cr | 8.38 Cr | 0.00 Cr | 0.00 Cr | 8.38 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 1.37 Cr | 8.57 Cr | 9.94 Cr | 0.00 Cr | 105.67 Cr | 244.32 Cr | 61.15 Cr | 329.84 Cr | 266.64 Cr |
| 2023-06-30 | -7.61 Cr | 15.22 Cr | 7.61 Cr | 0.00 Cr | 0.00 Cr | 7.61 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 0.26 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 5.47 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 0.89 Cr | 5.93 Cr | 0.00 Cr | 0.00 Cr | 5.93 Cr | 14.30 Cr | 8.38 Cr | 0.00 Cr | 5.93 Cr |
| 2023-09-30 | 0.95 Cr | 4.84 Cr | 0.00 Cr | 0.00 Cr | 4.84 Cr | 8.38 Cr | 3.54 Cr | 0.00 Cr | 4.84 Cr |
| 2023-06-30 | 0.08 Cr | 5.07 Cr | 0.00 Cr | 0.00 Cr | 5.07 Cr | 6.70 Cr | 1.64 Cr | 0.00 Cr | 5.07 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,748.00 | ₹4,193,941,440,000.00 | ₹1,148,922.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,045.00 | ₹1,604,760,105,000.00 | ₹449,981.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,140.00 | ₹1,062,717,300,000.00 | ₹535,042.00 |
| Mankind Pharma Limited | MANKIND | ₹2,404.00 | ₹991,838,762,080.00 | ₹567,777.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,158.10 | ₹964,828,188,462.00 | ₹1,248,300.00 |
| Lupin Limited | LUPIN | ₹2,035.00 | ₹929,215,595,000.00 | ₹558,111.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹880.90 | ₹886,388,007,000.00 | ₹783,082.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,159.80 | ₹673,614,159,600.00 | ₹645,512.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,950.00 | ₹591,846,750,000.00 | ₹53,048.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,393.00 | ₹393,105,993,000.00 | ₹479,938.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,356.00 | ₹344,022,624,000.00 | ₹153,297.00 |
| Laurus Labs Limited | LAURUSLABS | ₹589.05 | ₹317,646,979,650.00 | ₹1,383,505.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,531.10 | ₹316,164,763,200.00 | ₹45,303.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,076.90 | ₹274,141,048,500.00 | ₹138,631.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,524.00 | ₹237,251,748,000.00 | ₹135,150.00 |
| Piramal Enterprises Limited | PEL | ₹1,012.10 | ₹228,206,283,800.00 | ₹661,159.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹7,993.00 | ₹199,825,000,000.00 | ₹14,627.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,228.30 | ₹199,572,955,700.00 | ₹413,280.00 |
| Eris Lifesciences Limited | ERIS | ₹1,459.00 | ₹198,693,915,000.00 | ₹113,370.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹896.55 | ₹176,228,557,650.00 | ₹93,847.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,363.00 | ₹158,616,053,700.00 | ₹41,048.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹810.20 | ₹145,114,922,000.00 | ₹453,167.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,860.00 | ₹141,381,762,000.00 | ₹62,202.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹863.00 | ₹137,459,503,000.00 | ₹128,164.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹441.95 | ₹107,192,320,800.00 | ₹1,886,979.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,045.00 | ₹83,743,973,000.00 | ₹5,996.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹773.00 | ₹70,060,561,260.00 | ₹487,812.00 |
| FDC Limited | FDC | ₹430.00 | ₹70,008,300,000.00 | ₹84,454.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹638.95 | ₹62,483,495,555.00 | ₹133,815.00 |
| Strides Pharma Science Limited | STAR | ₹639.30 | ₹58,919,614,110.00 | ₹149,838.00 |
| Innova Captab Limited | INNOVACAP | ₹849.50 | ₹48,612,578,035.00 | ₹198,796.00 |
| Hikal Limited | HIKAL | ₹385.35 | ₹47,514,040,350.00 | ₹199,111.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹141.31 | ₹45,858,203,820.00 | ₹337,923.00 |
| Sequent Scientific Limited | SEQUENT | ₹160.98 | ₹40,293,615,960.00 | ₹1,484,319.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹778.00 | ₹39,459,459,800.00 | ₹21,883.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹560.00 | ₹39,427,248,000.00 | ₹31,585.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹423.00 | ₹38,607,210,000.00 | ₹570,318.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹355.00 | ₹35,598,690,000.00 | ₹51,448.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,042.00 | ₹33,772,638,000.00 | ₹9,278.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹57.00 | ₹31,233,378,000.00 | ₹7,592,577.00 |
| Suven Life Sciences Limited | SUVEN | ₹142.01 | ₹30,968,688,740.00 | ₹870,137.00 |
| Alembic Limited | ALEMBICLTD | ₹98.80 | ₹25,370,061,501.00 | ₹279,135.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹502.50 | ₹24,146,632,500.00 | ₹75,590.00 |
| Indoco Remedies Limited | INDOCO | ₹240.00 | ₹22,139,496,000.00 | ₹38,062.00 |
Key Executives
Whole Time Director
Mr. Kotian Chittananda Damodar
Gender: male
Year Born:
Whole Time Director
Mr. Himesh Virupakshaya
Gender: male
Year Born: 1961
Assistant Vice President of Sales & Marketing
Mr. D. L. Bhat
Gender: male
Year Born: 1963
Deputy General Manager of Internal Audit, Legal and Compliances
Mr. Ravindra Kumar Kothari
Gender: male
Year Born: 1955
Vice President of International Marketing & HR
Ms. Archana Dubey Mitra
Gender: female
Year Born: 1974
MD & Executive Director
Mr. Shailesh Dheerajmal Siroya
Gender: male
Year Born: 1966
Chief Financial Officer
Mr. Daddanala Venkat Bharath Bhushan
Gender: male
Year Born: 1989
Company Secretary & Compliance Officer
Mr. Abdul Basith
Gender: male
Year Born:
FAQs about Bal Pharma Limited
Who is the CEO of the company?
The CEO is Mr. Shailesh Dheerajmal Siroya.
What is the current market price of the stock?
The current price is ₹93.70.
What is the 52-week price range?
The range is ₹78.06-157.98.
What is the market capitalization of the company?
The market capitalization is ₹149.18 crores.
What is the dividend yield?
The dividend yield is 1.28%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 18.83.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Bal Pharma Limited (ISIN: INE083D01012) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹149.18 crores and an average daily volume of 86,326 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹1.2.